Syntara (ASX:SNT) has taken a significant step forward in the development of its next-generation topical anti-fibrotic therapy, announcing that its lead pan-lysyl oxidase inhibitor, SNT-9465, has completed a Phase 1a clinical trial and will now progress into a Phase 1b study in patients with hypertrophic scars. …
Syntara advances next-generation anti-fibrotic cream into Phase 1b trial
November 26, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News -
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - - Latest News -
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - - Latest News -
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech